Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (DE:2L9)
BERLIN:2L9
Blueprint Medicines (2L9) Stock Price & Analysis
0 Followers
2L9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€41.20 - €102.00
Previous Close€99.7
Volume68.00
Average Volume (3M)391.00
Market Cap
€6.23B
Enterprise Value€6.29B
Total Cash (Recent Filing)$710.64M
Total Debt (Recent Filing)$774.12M
Price to Earnings (P/E)N/A
Beta0.99
Next Earnings
Jul 31, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,616,902
10 Day Avg. Volume1
30 Day Avg. Volume391
Standard Deviation0.17
R-Squared0.12
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)51.39
Price to Sales (P/S)69.74
Price to Cash Flow (P/CF)-21.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue27.15
Enterprise Value/Gross Profit26.12
Enterprise Value/Ebitda-13.32
Forecast
1Y Price Target
€103.79Price Target Upside4.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Blueprint Medicines News
Bulls Say, Bears Say
Bulls Say
Drug Performance & SalesAyvakit's sales momentum is strong with a growth of 135% year-over-year, suggesting the drug has blockbuster potential and may significantly impact the company's financial health.
Financial PerformanceBlueprint Medicines Corporation's stock has a potential upside of approximately 31% with a raised price target to $125, signifying a positive sentiment from the financial community.
Operational EfficiencyBlueprint's R&D spend decreased by 21% year-over-year due to pipeline reprioritization, which could improve profitability and provide a more focused approach to research and development.
Bears Say
Drug PerformanceBezuclastinib exhibited reductions in clinical effectiveness measures that were less effective compared to Ayvakit.
Financial PerformanceDespite the positive sales performance, the analyst reiterates a Sell/High Risk rating with an expected share price return of -29.0%.
Market CompetitionCompetitive landscape shows other companies also developing mast cell-driven disease therapies, posing potential challenges to Blueprint's market position.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.77% Other Institutional Investors
99.23% Public Companies and
Individual Investors
2L9 FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was €41.20 and its highest was €102.00 in the past 12 months.
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is Jul 31, 2024 which is in 86 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on May 02, 2024. The company reported €1.353 earnings per share for the quarter, beating the consensus estimate of -€1.555 by €2.908.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Blueprint Medicines have?
Currently, no data Available
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of €1.353 in its last earnings report, beating expectations of -€1.555. Following the earnings report the stock price went up 15.592%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 75M.
---
Blueprint Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€103.79 (4.10% Upside)
€103.79 (4.10% Upside)
Blogger Sentiment
Bullish
DE:2L9 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.61%
12-Months-Change
Fundamentals
Return on Equity
-79.53%
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
2L9 Company Deck
---
2L9 Earnings Call
Q1 2024
0:00 / 0:00
---
2L9 Stock 12 Months Forecast
Average Price Target
€103.79
▲(4.10% Upside)
Technical Analysis
Best Analysts Covering 2L9
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+18.85%
reiterated a buy rating 4 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +18.85% per trade.
---